MAP4K2

Mitogen-activated protein kinase kinase kinase kinase 2

95,357 patent compounds predicted against MAP4K2, 67,315 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL44141	0.48	5/20
SCHEMBL147381	0.50	4/20
Linifanib (SCHEMBL93804)	1.00	3/20
SCHEMBL143765	0.82	3/20
SCHEMBL145998	0.82	3/20
SCHEMBL147845	0.73	3/20
SCHEMBL142970	0.72	3/20
SCHEMBL143788	0.71	3/20
SCHEMBL142448	0.67	3/20
SCHEMBL146016	0.64	3/20
SCHEMBL144273	0.63	3/20
SCHEMBL145151	0.63	3/20
SCHEMBL144892	0.61	3/20
SCHEMBL143798	0.61	3/20
SCHEMBL147370	0.60	3/20
SCHEMBL150090	0.60	3/20
SCHEMBL143006	0.59	3/20
SCHEMBL143225	0.59	3/20
SCHEMBL68662	0.58	3/20
SCHEMBL57834	0.58	3/20

Germline variants in MAP4K2 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full MAP4K2 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to MAP4K2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Molecular Mechanisms of Type 2 Diabetes Mellitus	PHASE4	COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer	PHASE2	COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant	PHASE2	RECRUITING
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...	PHASE2	COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer	PHASE2	COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery	PHASE2	COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer	PHASE2	COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial	nan	RECRUITING
Glutamate Supplementation in Young Men	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MAP4K2 binder may also engage these)

Protein	Name	Similarity
Q61161	—	1.000	Q61161 →
MAP4K1	Mitogen-activated protein kinase kinase kinase kinase 1	0.995	landscape →
P70218	—	0.990	P70218 →
Q8C6B2	—	0.983	Q8C6B2 →
Q99JP0	—	0.982	Q99JP0 →
Q3UFQ8	—	0.980	Q3UFQ8 →
Q8BYZ7	—	0.979	Q8BYZ7 →
Q8ND23	—	0.979	Q8ND23 →
Q9R011	—	0.978	Q9R011 →
Q9UJ98	—	0.978	Q9UJ98 →
P70268	—	0.978	P70268 →
Q5XHY1	—	0.977	Q5XHY1 →
Q6V7V2	—	0.976	Q6V7V2 →
Q9BUR4	—	0.976	Q9BUR4 →
Q9NY99	—	0.976	Q9NY99 →
A6QR40	—	0.976	A6QR40 →
Q86UX7	—	0.976	Q86UX7 →
Q3TJ91	—	0.975	Q3TJ91 →
Q96MI9	—	0.975	Q96MI9 →
Q1L8L6	—	0.975	Q1L8L6 →
Q9BST9	—	0.975	Q9BST9 →
Q6P1M3	—	0.975	Q6P1M3 →
Q96BJ8	—	0.975	Q96BJ8 →
Q8K045	—	0.974	Q8K045 →
Q8TE68	—	0.974	Q8TE68 →
Q9WV34	—	0.973	Q9WV34 →
Q5VV41	—	0.973	Q5VV41 →
PKN1	Serine/threonine-protein kinase N1	0.973	landscape →
ABHD16A	Phosphatidylserine lipase ABHD16A	0.973	landscape →
Q6ZT62	—	0.973	Q6ZT62 →